Cancer Data, AI, and Hype Detection

Educational orientation

Source-checked: 2026-06-05. This page is for critical thinking about data and AI, not clinical deployment guidance.

Core Idea

Cancer data can come from pathology, imaging, sequencing, registries, trials, wearables, claims, and notes. Each source has missingness, bias, measurement limits, and governance constraints. AI systems can help organize patterns, but a model is not clinically useful just because it scores well on a dataset.

Be suspicious of claims that skip cohort design, external validation, calibration, subgroup performance, and intended use.

Essential Vocabulary

• Leakage: training signal that would not exist in real use.
• External validation: testing in an independent setting.
• Calibration: whether probabilities match reality.
• Intended use: the exact task and context.

What This Does Not Mean

An AI demo, preprint, or leaderboard score is not evidence of patient benefit.

Builder/Data Lens

Before modeling, document provenance, labels, endpoints, splits, governance, and failure modes.

Go Deeper

• ML pitfalls in oncology
• AI and machine learning
• Datasets

References

1. National Cancer Institute. Cancer Statistics
2. U.S. Food and Drug Administration. AI/ML-Enabled Medical Devices